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The Bayesian Continual Reassessment Method
Using a Mixture-of-Uniforms Prior
Thomas M. Braun
Abstract
Traditionally, the Bayesian formulation of the Continual Reassessment Method
(CRM) is implemented with a one-parameter model describing the association of
dose with the probability of dose-limiting toxicity (DLT). Determination of the ap-
propriate value of the prior variance is often done via simulation over a grid search
of possible values until suitable operating characteristics are found. However, it is
under-appreciated that the operating characteristics for a given value of the prior
variance vary by the “skeleton,” which is the vector of a priori probabilities of
DLT for each dose. The skeleton implicitly leads to a set of indifference intervals,
with one interval for each dose, that contain values of the model parameter that
support each dose being the MTD. To remove the need of selecting a value for the
prior variance, we propose placing a uniform distribution over each of the indif-
ference intervals, making the prior distribution for the model parameter a mixture
of uniform distributions. Via simulation, we compare the operating characteristics
of the CRM using a traditional continuous prior to using the mixture-of-uniforms
prior in a variety of settings and show that the mixture-of-uniforms prior leads to
operating characteristics that are less sensitive to the chosen skeleton.
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1 Background and Signicance
Phase I clinical trials are typically the rst studies in humans of agents that have shown
promise for the treatment of cancer in pre-clinical animal studies. The goal of most Phase I
clinical trials is conceptually simple: to determine which doses of the agent can be given to
patients before an unacceptable fraction, 0<  < 1, of patients begins to experience dose-
limiting toxicities (DLTs). The largest dose studied that maintains a DLT fraction closest
to  is dened as the maximum tolerated dose (MTD). DLTs are very generally dened as
any Grade 3 (severe) or Grade 4 (life-threatening) non-hematologic side-eect or any Grade
4 hematologic side-eect, as dened by Common Toxicity Criterion (CTC) set forth by the
National Cancer Institute (NCI). Commonly used values of vary in the interval (0:20; 0:35),
depending upon the nature of the specic DLTs dened in the trial.
Given a pre-determined set of doses under study, the rst patient, or cohort of patients,
are usually assigned to the lowest dose. Assuming the number of observed DLTs remains
low, subsequent patients will be progressively assigned, or escalated, to higher doses. As the
trial progresses, eventually a dose will be assigned that results in DLTs occurring at a rate
felt to be unacceptable. At this point, the trial could be stopped, with the MTD identied
at one of the other assigned doses, or subsequent patients could be de-escalated, or assigned
to previously studied doses, with the possibility of later re-escalation in future patients, with
hopes of collecting more information as to where the MTD is located.
A variety of Phase I trial designs exist regarding how doses should be escalated and
de-escalated during the trial. Using the terms given by Tourneau (2009) and others,
existing trial designs are either \rule-based" or \model-based." Rule-based designs determine
the dose assignment for a patient or cohort of patients from the number of DLTs observed
in one or more of the most recently enrolled patients. The primary motivation of rule-
based designs is their simplicity for non-statistical investigators: once the rule is in place, no
mathematical computation beyond the proportion of observed DLTs is needed. Although
there are many rule-based designs such as the biased-coin design (BCD) (Stylianou and
2
http://biostats.bepress.com/umichbiostat/paper92
Flournoy, 2002) and the k-in-a-row design (Oron and Ho, 2009), the most prevalent rule-
based design in actual oncology Phase I trials is the 3+3 method; see Lin and Shih (2001) for
a more general discussion. In the 3+3 method, patients are enrolled in cohorts of three, with
each member of a cohort assigned to the same dose. If no patients in a cohort experience
DLT, the next cohort is assigned to the next higher dose. If two or three patients in a
cohort experience DLT, the trial is terminated, with the MTD dened at one dose below the
assignment of the current cohort. If one member of the cohort experiences DLT, another
cohort of three patients is assigned to the same dose. If no additional DLTs occur, the next
cohort is assigned to the next higher dose. However, if at least one additional DLT occurs,
the trial is terminated with the MTD dened at one dose below the assignment of the current
cohort. Although the 3+3 design is widely used because it is easy to administer, Ahn (1998),
Storer (1989), and Korn (1994), among others, have shown that the 3+3 design tends
to both identify the MTD at, and assign a large percentage of patients to, doses below the
MTD.
The genesis of model-based Phase I trial designs was publication of the Continual Re-
assessment Method (CRM) of O’Quigley, Pepe, and Fisher (1990), which was later modi-
ed by Faries (1994) and Goodman (1995). The CRM assumes that the probability
of DLT is related to dosed through a parametric function f (  ; d) that is monotonic in
dose. Two of the most commonly-used models are a one-parameter logistic regression model
f (d;  ) = exp(3 + d )=[1 + exp(3 + d )] and the so-called \empiric" modelf (  ; d) = d . A
prior distribution with mean  and variance  2 is placed on  and the posterior mean of
 is sequentially updated as each enrolled subject or cohort of subjects is observed for the
occurrence of DLT. The posterior mean of is then plugged back intof (  ; d) to compute an
updated probability of DLT for each dose. The dose with updated DLT probability closest
to  is then assigned to the next cohort of patients. Once all patients have been observed for
the possibilty of DLT, a nal updated DLT probability for each dose is computed, and the
MTD is dened as the dose whose updated probability is closest to . Although the CRM
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was rst proposed using Bayesian methods, a maximum-likelihood version of the CRM for
estimation of  was later proposed by O’Quigley and Shen (1996). An excellent tutorial on
the CRM was published by Garrett-Mayer (2006) and a recent survey of the CRM and later
extensions was published by O’Quigley and Conaway (2010).
One of the challenges of the one-parameter CRM model is determining an appropriate
value for  2. It is well-known that a very large, usually termed \non-informative," value of

2
, which is espoused with Bayesian analyses of large datasets, leads to poor performance of
the CRM at the beginning of the trial when few patients have been enrolled and little data
is available for computation of the posterior distribution of  . Thus, it is better to use a
slightly informative value for  2 so that the the prior distribution drives the computation of
the posterior distribution of  at the beginning of the study but allows for the data to drive
the computation of the posterior distribution of  near the end of the study.
However, the denition of \slightly informative" is subjective and usually has to be
determined through simulations over a range of possible values of 2 in a variety of settings
to determine which value or range of values for 2 leads to the best operating characteristics
of the CRM over all settings. One must also bear in mind that the value chosen for 2
is dependent upon the skeleton adopted for the CRM, so that if a dierent skeleton were
used, the operating characteristics when using 2 would change with the new skeleton. Real
examples of this phenomenon can be found in Moller (1995) and Neuenschwander
(2008), in which the supposed \aggressive" nature of the CRM can be fully explained by the
fact that the value of  2 used by each was too small for the skeleton each adopted.
A more systematic determination of 2 was recently developed by Lee and Cheung (2011),
who dened a \least-informative" value of  2 that is specic to: (a) the form of f (d;  ) used,
(b) the DLT probabilities for each dose, known as the \skeleton," and (c) the targeted
DLT rate  . Knowledge of these three values allows us to divide the positive real line intoJ
non-overlapping indierence intervals (Cheung and Chappell, 2002; Lee and Cheung, 2009),
one for each dosedj ; j = 1 ; 2; : : : ; J that denes a range of values for  for which dosedj
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would be the MTD. The width of interval j denes an probability that dose dj is
the MTD and the value of  2 that leads to a uniform distribution across the doses is selected
as the least-informative variance, denoted 2LI .
Our methods choose to use the indierence intervals in a slightly dierent fashion. Once
each indierence interval has been identied, we assume that conditional on being
in each interval,  has a uniform distribution over that interval, so that the marginal prior
distribution for  is a mixture of uniform distributions. Through use of this prior, we avoid
having to specify the prior variance 2. And given that dierent skeletons require dierent
values of  2 to obtain equal operating characteristics for the CRM, we expect that our
mixture-of-uniforms prior will reduce the variation in the performance of the CRM among
dierent skeletons. The Bayesian model averaging CRM (BMA-CRM) of Yin and Yuan
(2009a) and the recent work of Daimon (2011) were both motivated by the desire
to reduce the impact of skeleton choice on the performance of the CRM. However, both
methods are much more computationally intensive than our approach, which we denote the
uniform mixture CRM (UM-CRM).
We emphasize that we do not necessarily expect the UM-CRM to better identify the
MTD or assign more patients to the MTD than the traditional CRM among skeletons,
although it is likely that the UM-CRM will perform better than the traditional CRM with
some skeletons (and vice versa). We explain the specics of indierence intervals and the
details of our methods in Section 2, and we examine the performance of our methods via
simulation in Section 3. Concluding remarks can be found in Section 4.
2 Proposed Methods
We have a Phase I trial planning to enroll a maximum ofN patients, each of whom will be
assigned to one ofJ increasing doses. Each dosej = 1 ; 2; : : : J , has a probability of DLT, pj ,
with a corresponding skeleton valuepj supplied by investigators; the targeted DLT rate is
 . We assume that thepj can be modeled with a smooth function of dose,f (D j ;  ), where
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